Guangdong Hybribio Biotech Co.Ltd(300639) : the net profit in the first quarter is expected to be 360420 million yuan, with a year-on-year increase of 109.38% – 144.27%

Guangdong Hybribio Biotech Co.Ltd(300639) ( Guangdong Hybribio Biotech Co.Ltd(300639) ) disclosed the performance forecast for the first quarter of 2022 on March 31. The company expects to realize a net profit of 360420 million yuan attributable to the shareholders of the listed company from January to March, with a year-on-year increase of 109.38% – 144.27%. The announcement shows that during the reporting period, the company continued to promote the integrated business model of “nucleic acid testing products + medical testing services”, continued to implement the “nucleic acid 99 strategy” and “Kaipu B53 nucleic acid remote strategic service scheme”, actively gave full play to the company’s product technology and market advantages and strengthened market expansion. The company’s third-party medical laboratories (including Hong Kong) actively participated in epidemic prevention and control. Due to the increased demand for nucleic acid testing, the sales of sampling consumables and nucleic acid extraction reagents have been driven, and the company’s business has achieved rapid development.